A Real‐World Analysis of Outcomes in CIC‐Rearranged Sarcomas: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) Study
Open Access
- 19 January 2026
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 15 (1) , e71495
Abstract
Introduction: CIC‐rearranged sarcomas (CRS) are rare tumors predominantly affecting young adults. Despite distinct biology, CRS are often treated like Ewing sarcomas with multi‐agent chemotherapy, surgery, and radiotherapy, although the benefits of each remain unclear. We report the impact of treatment on response and survival. Methods: This retrospective multicenter study included patients diagnosed with CRS between 2002 and 2023. Demographic, treatment, and outcome data were collected. Event‐free (EFS) and overall survival (OS) were estimated using Kaplan–Meier analysis; risk factors were assessed via log‐rank tests and Cox regression. Treatment response was assessed using RECIST. Results: Among 27 patients (median age 21.5 years; range 8–83), 14 (52%) had localized and 12 (44%) metastatic disease (1 unknown). In the localized group, 6 (43%) received chemotherapy (Response: 2 complete, CR; 1 partial, PR; 1 mixed, MR; 1 stable, SD; 1 progressive disease, PD); 5 (36%) died—3 (21%) had received chemotherapy. Among metastatic patients, 10 (83%) received chemotherapy (1 CR, 5 PR, 2 MR, 1 PD); 9 died (one without chemotherapy). Local control was achieved in 12/14 (86%) localized and 7/12 (56%) metastatic patients. Only surgical resection was associated with improved OS (HR 0.13; p < 0.01) and EFS (HR 0.26; p < 0.01), particularly with R0 resection (EFS HR 0.23; p = 0.02). At median follow‐up of 18 months, 2‐year EFS was 56% vs. 8% ( p = 0.02) and OS was 67% vs. 23% ( p = 0.02) for localized vs. metastatic disease. Conclusion: Complete resection is critical in CRS. Chemotherapy benefit remains uncertain, underscoring the need for improved local control and novel, biology‐driven therapies.Keywords
This publication has 27 references indexed in Scilit:
- The 2020 WHO ClassificationAmerican Journal of Surgical Pathology, 2020
- The epigenomics of sarcomaNature Reviews Cancer, 2020
- Ewing‐like sarcoma: An emerging family of round cell sarcomasJournal of Cellular Physiology, 2018
- Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive OutcomeAmerican Journal of Surgical Pathology, 2017
- RECIST 1.1—Update and clarification: From the RECIST committeeEuropean Journal of Cancer, 2016
- CIC–DUX4 fusion‐positive round‐cell sarcomas of soft tissue and bone: a single‐institution morphological and molecular analysis of seven casesHistopathology, 2016
- CIC-rearranged SarcomasAmerican Journal of Surgical Pathology, 2016
- SarcomasPediatric Clinics of North America, 2015
- Soft tissue sarcomas at a glance: clinical, histological, and MR imaging features of malignant extremity soft tissue tumorsEuropean Radiology, 2009
- The Pathologist and the Residual Tumor (R) ClassificationPathology - Research and Practice, 1994